GLP‐1 RAs have been shown to reduce insulin resistance, which is strongly associated with the development and progression of NAFLD 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 (Figure 2). Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.